A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults.

Trial Profile

A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; MF 59
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 20 Jun 2013 Last checked against ClinicalTrials.gov record (Extension trial: NCT00912496).
    • 20 Jun 2013 Last checked against ClinicalTrials.gov record (Extension trial: NCT00912496).
    • 01 Mar 2012 Actual patient number of the extension trial is 637 as reported by ClinicalTrials.gov (NCT00912496).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top